Landmark trial for targeted drug

A major clinical trial has shown that a drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer.

33%

of men with treatment-resistant, advanced prostate cancer responded to olaparib

30%

of men had tumours with defects in their DNA repair systems and responded particularly well to olaparib

“Olaparib is highly effective at treating prostate cancer patients with DNA repair defects in their tumours”

"I hope it won’t be long before we are using olaparib in the clinic to treat prostate cancer, or before genomic stratification of cancers becomes a standard in this and other cancers."

Professor Johann de Bono

Further reading